Latest Breaking News On - Puma biotechnology inc - Page 13 : comparemela.com

Puma Biotech (PBYI) Granted FDA Orphan Drug Designation for Alisertib

Puma Biotech (PBYI) Granted FDA Orphan Drug Designation for Alisertib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlanh auerbachPuma biotechnology incDrug administrationPuma biotechnologyOrphan drug designationChief executive officerInvestigational new drug

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally.

United statesAlanh auerbachDrug administrationEuropean commissionPuma biotechnology incExchange commissionPuma biotechnologyOrphan drug designationChief executive officerInvestigational new drugAnnual report

Adaptive, efficient multi-arm phase 2 clinical trial for glioblastoma

Adaptive, efficient multi-arm phase 2 clinical trial for glioblastoma
sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.

United statesBrian alexanderEudocia quant leeIsabel arrillagaBristol myers squibb celgeneEli lillyPatrick wenRifaquat rahmanKeith ligonPuma biotechnology incBurroughs wellcome fundDivision of neuropathology at brighamNational brain tumor societyCelgene corporationIndividualized screening trialInnovative glioblastoma therapy

Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account for 42% of market growth

/PRNewswire/ The breast cancer monoclonal antibodies market is expected to grow by USD 15 billion from 2022 to 2027. In addition, the momentum of the market.

United kingdomUnited statesJesse maidaSeagen incMacrogenics incCelldex therapeutics incAmgen incGilead sciences incDaiichi sankyo coPuma biotechnology incBristol myers squibb coAstrazeneca plcEisai coJohnson services incCompany analysisCompany landscape

Dana-Farber leads adaptive, efficient multi-a

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.

United statesDana farber cancer instituteIsabel arrillagaNicole oliverioKeith ligonBristol myers squibb celgeneEudocia quant leePatrick wenRifaquat rahmanBrian alexanderEli lillyCelgene corporationPuma biotechnology incNational brain tumor societyCancer centerBurroughs wellcome fund